News | Thrombectomy Devices | May 21, 2018

Medtronic MindFrame Capture LP Revascularization Device Recalled

FDA warns of risk of delivery wire breaking or separating during use, which could cause device to be left in patient’s bloodstream

Medtronic MindFrame Capture LP Revascularization Device Recalled.

May 21, 2018 — Medtronic and the U.S. Food and Drug Administration (FDA) announced a Class I Urgent Medical Device Recall of the MindFrame Capture LP revascularization device on account of a risk of the delivery wire breaking or separating during use. The FDA said the clot retriever could be left inside the patient’s bloodstream, and this or the attempts made to retrieve the device, can lead to further complications; these complications include bleeding, additional blockage of blood vessels, more severe stroke symptoms or death.

On April 4, 2018, Medtronic followed up with their customers with another Urgent Medical Device Recall notice regarding patient management. The notice recommended healthcare providers to:

  • Review the notification and distribute the information to all appropriate personnel;
  • Follow up with the patient closely;
  • Consider antiplatelet therapy;
  • Consider repeating imaging on the patient; and
  • Complete and return the acknowledgement and receipt form to Medtronic.

The MindFrame Capture LP revascularization device is intended to restore blood flow or remove blood clots within a blood vessel in the brain during an acute ischemic stroke in patients who are ineligible for or fail intravenous tissue plasminogen activator (IV t-PA) therapy.

The total number of devices recalled in the U.S. has reached 529, according to the FDA. Product lot numbers affected by the recall are as follows: 300010, 300011, 300012, 300013, 300014, 300015, 300016, 300017 and 300018. Affected devices were manufactured between Feb. 3, 2016, and Jan. 14, 2018; they were distributed between March 18, 2016 and Jan. 17, 2018.

Customers with questions may contact Medtronic Quality Assurance by email at [email protected] or by phone at 1(800) 633-8766.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

  • Complete and submit the report online: www.fda.gov/MedWatch/report
  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

For more information: www.medtronic.com, www.fda.gov

Related Content

Sponsored Content | Videos | Cath Lab | October 24, 2018
Michael Flaherty, M.D., discusses a study published in Circulation Research which finds that use of hemodynamic suppo
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
Overlay Init